For the quarter ended March 2026, GoodRx Holdings, Inc. (GDRX) reported revenue of $194.01 million, down 4.4% over the same period last year. EPS came in at $0.07, compared to $0.09 in the year-ago quarter.
The reported revenue represents a surprise of +7.73% over the Zacks Consensus Estimate of $180.09 million. With the consensus EPS estimate being $0.07, the EPS surprise was -5.41%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Monthly Active Consumers: 5 compared to the 5 average estimate based on three analysts.
- Subscription plans: 717 versus the two-analyst average estimate of 679.
- Revenue- Prescription transactions: $113.69 million versus $114.73 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -23.7% change.
- Revenue- Other: $3.69 million versus the three-analyst average estimate of $3.99 million. The reported number represents a year-over-year change of -15.8%.
- Revenue- Pharma direct: $52.23 million versus the three-analyst average estimate of $40.07 million. The reported number represents a year-over-year change of +82.3%.
- Revenue- Subscription: $24.39 million versus $21.68 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change.
View all Key Company Metrics for GoodRx here>>>
Shares of GoodRx have returned +24.9% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
